Table 7 Genotype distribution and allelic frequency of TGF-β1 (+915G>C) in controls and patients with ovarian cancer according to ages subtypes

TGF-β1 (+915G>C) genotype (N, %)

 Age

45–55 y

 G/G

29 (87.9%)

23 (69.7%)

P < 0.05

1

 G/C

4 (12.1%)

10 (30.3%)

P < 0.05

3.15 (0.87–11.36)

 C/C

0

0

–

–

 G

62 (94%)

56 (85%)

NS

0.361 (0.107–1.217)

 C

4 (6%)

10 (15%)

NS

2.768 (0.822–9.324)

 Dominant model (GC + CC vs. GG) GC + CC

4 (12.1%)

10 (30.3%)

P < 0.05

3.152 (0.875–11.362)

 Recessive model (CC vs. GG + GC) GG + GC

33 (100%)

33 (100%)

–

1.0

 CC

0

0

–

–

 Age

56–65 y

 G/G

8 (88.9%)

3 (37.5%)

P < 0.05

1

 G/C

0 (0%)

5 (62.5%)

P < 0.05

2.667 (1.090–6.524)

 C/C

1 (11.1%)

0 (0%)

NS

0.889 (0.706–1.120)

 G

16 (89%)

11 (69%)

NS

0.275 (0.045–1.681)

 C

2 (11%)

5 (31%)

NS

3.636 (0.595–22.234)

 Dominant model (GC+CC vs. GG) GC+CC

1 (11.1%)

5 (62.5%)

P < 0.05

13.33 (1.07–166.38)

 Recessive model (CC vs. GG+GC) GG+GC

8 (88.9%)

8 (100%)

NS

1.0

 CC

1 (11.1%)

0 (0%)

NS

0.500 (0.306–0.816)

 Age

66–80 y

 G/G

4 (66.7%)

5 (71.4%)

NS

1

 G/C

2 (33.3%)

2 (28.6%)

NS

0.80 (0.08–8.47)

 C/C

0

0

–

–

 G

10 (83%)

12 (86%)

NS

1.2 (0.142–10.119)

 C

2 (17%)

2 (14%)

NS

0.833 (0.099–7.027)

 Dominant model (GC+CC vs. GG) GC+CC

2 (33.3%)

2 (28.6%)

NS

0.8 (0.076–8.474)

 Recessive model (CC vs. GG+GC) GG+GC

6 (100%)

7 (100%)

1.0

 CC

0

0

–

–